AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06707532
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction of anaesthesia:~* Fentanyl 1-3ug/kg/m.c i.v.~* Ketamine 50mg i.v.~* Propofol 1.5-2mg/kg/m.c i.v.~* Rocuronium 5mg (b.w.\<60kg) 10mg (b.w.\>60kg) i.v. Precurarisation~* Chlorucinylcholine 1-1.5mg/kg/m.c i.v. -\> Intubation~Application (cycle of 5 pulses with 2000V biphasic alternating current) - during PFA:~- In case of ventilatory distress pPeak \>30 cm H2O ad hoc Propofol 0.25-0.75mg/kg/m.c i.v.~Elimination of neuromuscular blockade:~- To exclude residual relaxation after pre-curative: 1mg Atropine i.v. + 0.5mg Neostigmine i.v.
Trial: NCT06707532
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction of anaesthesia:~* Fentanyl 1-3ug/kg/m.c i.v.~* Ketamine 50mg i.v.~* Propofol 1.5-2mg/kg/m.c i.v.~* Rocuronium 5mg (b.w.\<60kg) 10mg (b.w.\>60kg) i.v. Precurarisation~* Chlorucinylcholine 1-1.5mg/kg/m.c i.v. -\> Intubation~Application (cycle of 5 pulses with 2000V biphasic alternating current) - during PFA:~- rocuronium 0.1-0.3mg/kg/m.c i.v. For TOF \<2~Abolition of neuromuscular blockade:~- Atropine 1-1.5mg i.v. + 1-3mg Neostigmine i.v. Or Sugammadex 2-4mg/kg/m.c i.v.
Trial: NCT04811040
Drug: Oral Lenacapavir
RxNorm normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered without regard to food
Trial: NCT04811040
Drug: Subcutaneous Lenacapavir
RxNorm normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered in the abdomen via subcutaneous injections
Trial: NCT04811040
Drug: Teropavimab
RxNorm normalized name: Teropavimab
DrugBank: Teropavimab (DB18916)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT04811040
Drug: Zinlirvimab
RxNorm normalized name: Zinlirvimab
DrugBank: Zinlirvimab (DB18867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05367492
Drug: Double Blind Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For participants 16-17 years old, ≤ 55 kg:~* 0.5 mg once daily for 7 days, then~* 0.5 mg twice daily for 11 weeks~For participants 16-17 years old, \>55 kg:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks~For participants 18+ years old:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks
Trial: NCT04229979
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: injection
Trial: NCT04229979
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tablet
Trial: NCT04229979
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection
Trial: NCT04229979
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: injection
Trial: NCT05237388
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One pill daily
Trial: NCT05353374
Drug: Sodium Fusidate 2 % Topical Ointment
RxNorm normalized name: sodium fusidate 2 % Topical Ointment
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fusidate 2% topical ointment was applied twice daily on the wound after cauterization for 14 days.
Trial: NCT05353374
Drug: Petrolatum ointment
RxNorm normalized name: GERI PROTECT Petrolatum Ointment
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Petrolatum ointment was applied twice daily on the wound after cauterization for 14 days.
Trial: NCT04817618
Drug: iptacopan
RxNorm normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
Trial: NCT05583006
Drug: tenofovir alafenamide (TAF)
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TAF switch therapy in CHB patients who are unsatisfied to ETV therapy.
Trial: NCT04949841
Drug: Delgocitinib
RxNorm normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Delgocitinib cream 20 mg/g
Trial: NCT05306379
Drug: Voclosporin
RxNorm normalized name: Voclosporin
DrugBank: Voclosporin (DB11693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dose 23.7 mg twice daily
Trial: NCT06052618
Drug: Pacritinib
RxNorm normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pacritinib is administered orally as 200 mg twice daily for a total of 6, 28-day cycles
Trial: NCT05544812
Drug: Sintilimab ，bevcizumab/cetuximab，XELOX
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients in this group had previously received the following treatment regimens:~Oxaliplatin :130 mg/m2, D1, Q3W; Capecitabine :1000mg/m2, bid q2w Sintilimab for injection :200mg, D1, Q3W Bevacizumab :7.5mg/kg, D1, Q3W or cetuximab :500 mg/m, D1, Q2W
Trial: NCT05446168
Drug: tributyrin
RxNorm normalized name: Tributyrin
DrugBank: Tributyrin (DB12709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.
Trial: NCT05737121
Drug: VNX001
DrugBank: NX001 (DB18099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VNX001 (alkalinized lidocaine HCl and heparin sodium)
Trial: NCT05737121
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alkalinized lidocaine hydrochloride
Trial: NCT06316427
Drug: Autologous CD7 CAR T-cell
RxNorm normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from patients.
Trial: NCT06316427
Drug: Prior-HSCT donor-derived CD7 CAR T-cell
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from prior-HSCT donors.
Trial: NCT06316427
Drug: New donor-derived CD7 CAR T-cell
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from new donors.
Trial: NCT05011851
Drug: NNZ-2591
RxNorm normalized name: NNZ-2591
DrugBank: NNZ-2591 (DB15601)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
Trial: NCT06043674
Drug: Glofitamab
RxNorm normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2:1 T-cell bispecific humanized monoclonal antibody, 2.5 mL or 10 mL single-use vial, via intravenous infusion per protocol.
Trial: NCT06043674
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Humanized glycoengineered type II anti-CD20 monoclonal antibody, 50 mL single-use vial, via intravenous infusion per protocol.
Trial: NCT06043674
Drug: Polatuzumab Vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Antibody-drug conjugate, 30 mg or 140 mg vial, via intravenous infusion per protocol.
Trial: NCT06043674
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Humanized immunoglobulin monoclonal antibody, 840 mg/14 mL or 1200 mg/20 mL single-use vial, via intravenous infusion per protocol.
Trial: NCT06043674
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For the treatment of Cytokine Release Syndrome. Recombinant, humanized, anti-human monoclonal antibody, 20 mg/mL single-dose vials, via intravenous infusion per protocol.
Trial: NCT05406362
Drug: VAD044 Part I
RxNorm normalized name: VAD044
DrugBank: VAD-044 (DB17697)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules to be taken once daily for 12 weeks
Trial: NCT05227742
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral psilocybin once per week for 5 weeks.
Trial: NCT05657925
Drug: ondansetron 8 mg
RxNorm normalized name: ondansetron 8 MG
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg prn sublingually when awakening with nausea. as per the FDA label for ondansetron.
Trial: NCT05688449
Drug: Bupivacaine-fentanyl
RxNorm normalized name: Bupivacaine-Fentanyl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A 20 ml bolus of 2 mcg/ml fentanyl + 0.125% bupivacaine solution will be administered to the bupivacaine group via the epidural catheter, and 5ml/hour infusion will be started.
Trial: NCT05688449
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A 20 ml bolus of saline will be administered to the saline group via the epidural catheter, and 5ml/hour infusion will be started.
Trial: NCT06467942
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
DrugBank: Butylene glycol (DB14110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Chinese medicine group
Trial: NCT06467942
Drug: Lactobacillus
RxNorm normalized name: lactobacillus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Lactobacillus group
Trial: NCT05974748
Drug: Sodium hypochlorite 5.25%
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participants will be randomly divided into two groups using the sealed envelope method during the instrumentation process. The clinician will use the irrigation in accordance with the protocol. Between each instrument in group A, 3 ml of 5.25% sodium hypochlorite (NaOCl) will be used to irrigate each canal.
Trial: NCT06038981
Drug: Administration of 1g tranexamic acid intravenous bolus, after anesthesia was introduced
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The systemic use of tranexamic acid (TXA) has been shown to be effective in many types of surgery, reducing the incidence of post-operative bleeding and thereby reducing the rate of reoperation.~To evaluate if TXA systemic administration reduces postoperative blood loss in bariatric surgeries (sleeve gastrectomy operation)
Trial: NCT00002121
Drug: Diethylhomospermine
RxNorm normalized name: Diethylhomospermine
DrugBank: Diethylhomospermine (DB13011)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05707936
Drug: Normal Saline Flush 20 ml
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal Saline Flush 20 ml
Trial: NCT05707936
Drug: Normal Saline Flush 10 ml
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal Saline Flush 10 ml
Trial: NCT05207670
Drug: Mosunetuzumab (Cohorts A-C)
RxNorm normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SC mosunetuzumab for up to 17 cycles and for optional maintenance (Cohort A only)
Trial: NCT05207670
Drug: Mosunetuzumab (Cohorts D-E)
RxNorm normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SC mosunetuzumab for up to 34 cycles
Trial: NCT05877820
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral tablet
Trial: NCT05207670
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab
Trial: NCT06482593
Drug: AH-Plus Epoxy Resin Sealer
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentsply AH Plus Root Canal Sealing Material is a two-component paste/paste root canal sealer based on epoxy-amine resin. The AH Plus sealer shows extremely low shrinkage making it a suitable choice of material to seal the root canal.
Trial: NCT04539873
Drug: Colchicine 0.5 MG
RxNorm normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patientes in this arm will receive study medication colchicine 1,5 orally on the first day (initially two pills of 0,5 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. The duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.
Trial: NCT00418249
Drug: AS101
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04899427
Drug: orelabrutinib
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib will be given as 150mg per day orally, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
Trial: NCT04899427
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
Trial: NCT04899427
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
Trial: NCT05296733
Drug: BI 456906
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 456906
Trial: NCT00002451
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002451
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00002451
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00002451
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06428682
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental group will receive TXA intraoperatively (15mg/kg IV, once at beginning of case then re dose at 4hrs if operation goes longer) at the time of their surgery.
Trial: NCT03532958
Drug: BNZ-1
RxNorm normalized name: BNZ-1
DrugBank: EQ101 (DB17396)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGylated peptide inhibitor of IL-2, IL-9, and IL-15
Trial: NCT04940767
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin is a retinoic acid analogue (13-cis-retinoic acid) supplied as oral capsules. and was approved in the US for the treatment of severe acne vulgaris in 1982 under the brand name Accutane®.
Trial: NCT04811261
Drug: Intravenous Infusion of UCLSCs
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The first 3 subjects will be administered 50 x 10\^6 ULSCs reconstituted in PBS with 1% human serum albumin in a volume of 250 ml, and monitored for adverse events or toxicities, immediately following dosing, and again at 30 days.
Trial: NCT05435209
Drug: Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
RxNorm normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gardasil
Trial: NCT05088720
Drug: misoprostol 800 µg
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
Trial: NCT05088720
Drug: misoprostol 400 µg
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: received misoprostol 400 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
Trial: NCT06041490
Drug: multi-kinase inhibitors in combination with bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The eligible participants will start taking multi-kinase inhibitors between 4-8 weeks after liver transplantation. The choice of the specific multi-kinase inhibitor, including sorafenib, lenvatinib, or regorafenib, will be determined by the researchers based on factors such as the participant's tumor characteristics, liver function, physical condition, risk of side effects, economic status, and personal preference. The specific dosage and administration details can be found in the table provided. The maximum duration of multi-kinase inhibitor treatment will be 12 months or until any of the following conditions occur, whichever comes first: 1) The participant experiences intolerable toxic reactions that do not alleviate with dose adjustments, or 2) The participant has documented disease recurrence confirmed through imaging or withdraws from the study for other reasons.
Trial: NCT00046878
Drug: O6-benzylguanine
RxNorm normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00046878
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05055128
Drug: X842 Dummy
RxNorm normalized name: Acaciae gummi
DrugBank: Acacia (DB10451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive matching placebo tablets for X842.
Trial: NCT05055128
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive Lansoprazole capsule.
Trial: NCT05055128
Drug: Lansoprazole Dummy
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive matching placebo capsules for Lansoprazole.
Trial: NCT05116007
Drug: AK112
RxNorm normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05116007
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
Trial: NCT05116007
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4)
Trial: NCT05208112
Drug: M6229
RxNorm normalized name: Metformin hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Continuous intravenous infusion of M6229, a low-anticoagulant fraction of heparin. Dose-escalation is based on a modified continual reassessment method (mCRM) including escalation with overdose control (EWOC).
Trial: NCT04935359
Drug: NIS793
RxNorm normalized name: Anti-tgf-beta monoclonal antibody nis793
DrugBank: Nisevokitug (DB17561)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrate for solution infusion (Liquid in Vial)
Trial: NCT04935359
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Per locally approved formulation
Trial: NCT04935359
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Per locally approved formulation
Trial: NCT06276868
Drug: Dalcilib+letrozole+HP treatment group
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants received 150mg of darcilib once a day. Take it continuously for 21 days, then stop taking it for 7 days, with a treatment cycle of 28 days.~Letrozole 2.5mg once daily (premenopausal patients treated with OFS); Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Patuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, or fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 weeks.
Trial: NCT06088290
Drug: Lurbinectedin
RxNorm normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Infusion